PolyPid PYPD 深 沪
等待开盘 11-13 09:30:00 美东时间
3.75
-0.010
-0.27%
华盛通- 最 高3.78
- 今 开3.75
- 成交量 10.28万股
- 最 低 3.60
- 昨 收 3.76
- 总市值 5961.45万
- 52周最高 3.93
- 市盈率 静 --
- 换手率 0.65%
- 52周最低 2.30
- 委 比 31.58%
- 总股本 1589.72万
- 历史最高 583.50
- 量 比 1.43
- 振 幅 4.79%
- 历史最低 2.30
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PolyPid Advances D-PLEX₁₀₀ Towards FDA Submission and Commercial Readiness
PolyPid ( ($PYPD) ) has shared an announcement. PolyPid Ltd. announced its thir...
11-12 20:56
PolyPid Q3 EPS $(0.37) Beats $(0.44) Estimate
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.44) by 15.53 percent. This is a 69.67 percent increase over losses of $(1.22) per share from the same
11-12 20:30
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
PolyPid's D-PLEX₁₀₀, designed to prevent surgical site infections (SSIs) via extended, localized antibiotic delivery, has been named "Therapeutics Solution of the Year" by BioTech Breakthrough. With Phase 3 results showing a 58% relative risk reduction in SSIs, the product, leveraging PolyPid's PLEX technology, delivers doxycycline for 30 days directly at the surgical site. Widespread SSIs remain a critical issue, causing extended hospital stays ...
11-06 13:30
PolyPid Announces That Dr. Shmuel Sharoni Will Present Topline Phase 3 Shield II Trial Results For D-PLEX₁₀₀ At The 2025 American College Of Surgeons Clinical Congress In Chicago
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dr. Shmuel Sharoni will present the topline results from the Company's
09-30 20:50
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
PolyPid Ltd. announced that Dr. Shmuel Sharoni will present topline results from the successful Phase 3 SHIELD II trial of D-PLEX₁₀₀ at the 2025 American College of Surgeons (ACS) Clinical Congress in Chicago. The trial demonstrated a 38% reduction in surgical site infections, reinterventions, or mortality compared to standard of care alone. PolyPid plans to submit an NDA for D-PLEX₁₀₀ in early 2026. The company specializes in locally administere...
09-30 12:45
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference
PolyPid Ltd. will present at the Lytham Partners Fall 2025 Virtual Investor Conference on September 30, 2025, and participate in one-on-one meetings. Management will also attend the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025. Investors can arrange meetings via Lytham Partners or ROTH representatives. PolyPid, a biopharma company, aims to improve surgical outcomes using its PLEX technology. Its lead product, D-PLEX₁₀₀, ...
09-17 12:44
PolyPid Completes Key GMP Inspection for D-PLEX100 Manufacturing Readiness
The latest update is out from PolyPid ( ($PYPD) ). PolyPid Ltd. announced on Se...
09-16 20:59
PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀
PolyPid Ltd. successfully completed its fourth consecutive GMP inspection, confirming its manufacturing facility meets EU and US standards. This milestone supports its planned 2026 NDA submission for D-PLEX₁₀₀, its lead product for preventing surgical site infections, following positive Phase 3 results. The inspection also prepares the company for FDA inspection and potential market entry in both the U.S. and Europe. D-PLEX₁₀₀ has shown significa...
09-16 12:30
PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, announced that its senior management will participate in the 27th Annual H.C. Wainwright Global Investment Conference on September 8-9, 2025. The company will host a fireside chat with H.C. Wainwright Managing Director Brandon Folkes on September 8, alongside virtual and in-person investor meetings. PolyPid specializes in controlled drug delivery u...
09-03 12:30
